1. Search Result
Search Result
Results for "

SPR

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

6

Peptides

1

Inhibitory Antibodies

1

Natural
Products

4

Recombinant Proteins

1

Antibodies

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128780B
    SPR206 acetate
    1 Publications Verification

    Bacterial Antibiotic Infection
    SPR206 acetate is a polymyxin analog with antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. SPR206 acetate has an anti-bacterial infection effect by interacting with the bacterium’s outer membrane. The MIC values of SPR206 acetate against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301 are both 0.125 mg/L .
    SPR206 acetate
  • HY-P1649B
    SPR741 acetate
    3 Publications Verification

    NAB741 acetate

    Bacterial Antibiotic Infection
    SPR741 acetate (NAB741 acetate) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 acetate increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 acetate inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 acetate .
    SPR741 acetate
  • HY-115510

    SPRi3

    Others Inflammation/Immunology
    SPR inhibitor 3 (SPRi3) is a potent sepiapterin reductase (SPR) inhibitor. SPR inhibitor 3 (SPRi3) displays high binding affinity to human SPR in a cell-free assay (IC50=74 nM) and efficiently reduces biopterin levels in a cell-based assay (IC50=5.2 μM). SPR inhibitor 3 (SPRi3) reduces neuropathic and inflammatory pain through a reduction of BH4 levels .
    SPR inhibitor 3
  • HY-150506

    Parasite Infection
    SPR7 (compound 7) is a potent and selective rhodesain inhibitor, with a Ki of 0.51 nM. SPR7 shows antiparasitic activity against T. b. brucei, with an EC50 of 1.65 μM .
    SPR7
  • HY-152222

    SARS-CoV Cathepsin Infection
    SPR38 is a potent SARS-CoV-2 main protease inhibitor, with a Ki of 0.260 μM. SPR38 also inhibits hCatL and hCatB, with Ki values of 1.92 μM and 11.1 μM, respectively .
    SPR38
  • HY-P1649

    NAB741

    Bacterial Antibiotic Infection
    SPR741 (NAB741) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 .
    SPR741
  • HY-152224

    SARS-CoV Infection
    SPR41 is a potent SARS-CoV-2 main protease inhibitor with Ki values of 0.184, 0.252, 14.4 µM for SARS-CoV-2 M pro, hCatL, hCatB, respectively. SPR41 shows antiviral and cytotoxicity .
    SPR41
  • HY-152220

    SARS-CoV Infection
    SPR39 is a potent SARS-CoV-2 main protease inhibitor with Ki values of 0.252, 3.38, 7.88 µM for SARS-CoV-2 M pro, hCatL, hCatB, respectively. SPR39 shows antiviral and cytotoxicity .
    SPR39
  • HY-135655A

    SPR720; pVXc-486

    Bacterial Infection
    Fobrepodacin (SPR720) is an orally active and potent phosphate proagent of SPR719 (VXc-486; HY-12930). Fobrepodacin has potent bactericidal activities in vivo .
    Fobrepodacin
  • HY-P1649A

    NAB741 TFA

    Bacterial Antibiotic Infection
    SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 TFA increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 TFA inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 TFA .
    SPR741 TFA
  • HY-12930
    SPR719
    4 Publications Verification

    VXc-486

    Topoisomerase Bacterial Infection
    SPR719 (VXc-486) is a gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively .
    SPR719
  • HY-RS13708

    Small Interfering RNA (siRNA) Others

    SPR Human Pre-designed siRNA Set A contains three designed siRNAs for SPR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SPR Human Pre-designed siRNA Set A
    SPR Human Pre-designed siRNA Set A
  • HY-135655

    SPR720 disodium; pVXc-486 disodium

    Bacterial Infection
    Fobrepodacin (SPR720) disodium is an orally active and potent phosphate proagent of SPR719 (VXc-486; HY-12930). Fobrepodacin disodium has potent bactericidal activities in vivo .
    Fobrepodacin disodium
  • HY-128780

    SPR206

    Bacterial Infection Cancer
    Upleganan (SPR206), a polymyxin analogue, and shows antibiotic activity against multidrug resistant Gram-negative pathogen. The MIC values of Upleganan against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301 are both 0.125 mg/L .
    Upleganan
  • HY-P3852

    SPR393-407

    Neurokinin Receptor Neurological Disease Inflammation/Immunology
    Neurokinin Receptor (393-407), rat (SPR393–407) is a rat neurokinin 1 receptor (NK1R) fragment. NK1R is rapidly internalized by endocytosis and recycled to the plasma membrane when binding to substance P (SP). Neurokinin Receptor (393-407), rat can be used in the research of neurogenic inflammation .
    Neurokinin Receptor (393-407), rat
  • HY-113603

    SPR001; LY2371712

    CRFR Cancer
    Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .
    Tildacerfont
  • HY-160481

    Tau Protein MicroRNA Neurological Disease
    MG-1102 is first-in-class dual binder of monomeric tau and pre-miRNA-146a. MG-1102 shows specific inhibition of miRNA146a with IC50s of 0.21 mM and 0.36 mM specific inhibition of doublelabeled pre-miRNA146a and mono-labeled pre-miRNA146a, respectively. MG-1102 interacts with tau monomers with a Kd of 3.21 mM by surface plasmon resonance (SPR). MG-1102 is a potential multi-target-directed ligands (MTDLs) for Alzheimer’s disease (AD) .
    MG-1102
  • HY-160477

    PIKfyve NF-κB IKK Inflammation/Immunology
    DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with an estimated KD constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .
    DC-SX029
  • HY-116992

    Demosan; TERSAN SP(R)

    Others Infection
    Chloroneb (Demosan) is a pesticide with fungicidal and plant-protective activities. Chloroneb can be used to detect organochlorine pesticide residues, showing good selectivity, stability and reproducibility. Chloroneb has been applied to the detection of licorice, cucumber, river water and soil samples with satisfactory results .
    Chloroneb
  • HY-114388
    QM385
    2 Publications Verification

    Others Inflammation/Immunology
    QM385 is a potent sepiapterin reductase (SPR) inhibitor with an IC50 of 1.49 nM, which blocks T-cell proliferation and autoimmunity at nanomolar potency and with good oral bioavailability .
    QM385
  • HY-101533
    AZD-5991
    5+ Cited Publications

    Bcl-2 Family Cancer
    AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay .
    AZD-5991
  • HY-P9905
    Cetuximab
    Maximum Cited Publications
    30 Publications Verification

    C225

    Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
    Cetuximab
  • HY-168536

    Others Cancer
    SJ46411 is a potent ligand for KLHDC2, with a Kd of ~260 nM measured by isothermal titration calorimetry (SPR Kd = 0.5 μM, TR-FRET IC50 = 3.9 μM, ΔTm = 6.0 °C) .
    SJ46411
  • HY-168535

    Ligands for E3 Ligase Cancer
    SJ6145 is a potent ligand for KLHDC2 SBD, with the Kd of 16.9 μM in SPR test, IC50 value of 42 μM in inhibiting KLHDC2 SBD binding to a di-Gly degron peptide test .
    SJ6145
  • HY-162960

    Ras Cancer
    pan-KRAS degrader 1 (Compound 1) is a panKRAS degrader with a surface plasmon resonance (SPR) dissociation constant Ki value of 25 nM for KRAS G12V .pan-KRAS degrader 1 has antitumor activity .
    pan-KRAS degrader 1
  • HY-13963
    ZCL278
    2 Publications Verification

    Flavivirus Dengue virus VSV Ras Cancer
    ZCL278 is a selective Cdc42 modulator that directly binds to Cdc42 and inhibits its functions with Kd of 11.4 μM for Cdc42-ZCL278 affinity in surface plasmon resonance (SPR) experiment.
    ZCL278
  • HY-Y1049

    Bacterial Infection
    2-Amino-6-bromopyridine (compound 7) is a PqsR ligand with a Kd values of 6.8 μM in the SPR assay. 2-Amino-6-bromopyridine shows a weak antagonistic activity .
    2-Amino-6-bromopyridine
  • HY-159652

    Ras Cancer
    KRAS inhibitor-31 (compound 33) is a KRAS inhibitor, with KD (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .
    KRAS inhibitor-31
  • HY-101964

    SHP2 Phosphatase Cancer
    SPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC50s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively .
    SPI-112
  • HY-101533B

    Bcl-2 Family Cancer
    AZD-5991 S-enantiomer is the less active enantiomer of AZD-5991. AZD-5991 S-enantiomer is a Mcl-1 inhibitor with an IC50 of 6.3 μM in FRET assay and a Kd of 0.98 μM in surface plasmon resonance (SPR) assay.
    AZD-5991 (S-enantiomer)
  • HY-101931

    VEGFR Cancer
    hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a Kd of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression .
    hVEGF-IN-1
  • HY-135691

    c-Myc Apoptosis Cancer
    hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with Kd values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities .
    hnRNPK-IN-1
  • HY-122611

    Androgen Receptor Apoptosis Cancer
    CSRM617 is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a Kd of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 induces apoptosis by appearance of cleaved Caspase-3 and PARP. CSRM617 is well tolerated in the prostate cancer mouse model
    CSRM617
  • HY-122611A
    CSRM617 hydrochloride
    1 Publications Verification

    Androgen Receptor Apoptosis Cancer
    CSRM617 hydrochloride is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a Kd of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 hydrochloride induces apoptosis by appearance of cleaved Caspase-3 and PARP. CSRM617 hydrochloride is well tolerated in the prostate cancer mouse model
    CSRM617 hydrochloride
  • HY-P3143A

    PD-1/PD-L1 Cancer
    BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57 hydrochloride
  • HY-P3143

    PD-1/PD-L1 Cancer
    BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50?of 7.68?nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs .
    BMSpep-57
  • HY-161841

    FGFR Cancer
    Antitumor agent-177 (compound 57), a non-steroidal NSC12 derivative, shows potent FGF2 binding affinity with a Kd of 24 μM by SPR. Antitumor agent-177 significantly inhibits the formation of HSPG/FGF2/FGFR1 ternary complexes. Antitumor agent-177 inhibits FGFR activation and exerts a potent anti-tumor activity on multiple myeloma (MM) cell lines in vitro and in vivo .
    Antitumor agent-177
  • HY-169311

    Ras Cancer
    KRAS inhibitor-37 (compound 2) is a potent KRAS inhibitor with KDs of 0.004 nM, 0.041 nM, 0.019 nM and 0.144 nM for KRAS wild type, KRAS G12D, KRAS G12C and KRAS G12V by SPR binding assay, respectively. KRAS inhibitor-37 inhibits cell proliferation with IC50s of <2 nM-14 nM for H358, SW620, PANC08.13 cells, respectively. KRAS inhibitor-37 has the potential for cancer research .
    KRAS inhibitor-37

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: